The Food and Drug Administration (FDA) reports that Bicillin L-A (penicillin G benzathine Pfizer) Injection is available and is on allocation.
The initial shortage was announced on April 29, 2016 due to manufacturing delays. As of July 8, 2016, Bicillin L-A 600,000U Pediatric Injection and 2,400,000U/4mL strengths are available and the 1,200,000U/2mL strength is currently on allocation. Wholesalers and distributors should be contacted to confirm inventory.
Bicillin L-A is a penicillinase-sensitive penicillin indicated for susceptible infections, including mild to moderate upper respiratory strep infections and syphilis. Benzathine penicillin G is the recommended treatment for syphilis and is the only option for pregnant women infected with or exposed to syphilis. It is also indicated as follow-up prophylaxis of rheumatic heart disease and acute glomerulonephritis.
For more information call (800) 533-4535 or visit FDA.gov.